Companion Diagnostic Stocks List Ranked for 2024 |

Symbol	Grade	Name	% Change
MYGN	F	Myriad Genetics, Inc.	-1.18
BDSX	F	Biodesix, Inc.	0.84
QGEN	D	Qiagen N.V.	0.57
VSTM	D	Verastem, Inc.	3.69

Related Industries: Biotechnology Diagnostics & Research

Symbol	Grade	Name	Weight
GNOM	F	Global X Genomics & Biotechnology ETF	6.89
EKG	B	First Trust Nasdaq Lux Digital Health Solutions ETF	4.24
PBE	D	PowerShares Dynamic Biotech & Genome	4.2
EDOC	B	Global X Telemedicine & Digital Health ETF	3.95
WDNA	D	WisdomTree BioRevolution Fund	2.14

Compare ETFs

Compare EKG to PBE Compare EKG to WDNA Compare GNOM to PBE

Date	Stock	Title
Nov 20	MYGN	Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Nov 20	QGEN	Morgan Stanley lists hedge funds’ largest Q3 ownership increases in Russell 1000 stocks
Nov 20	BDSX	Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nov 19	MYGN	Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Nov 19	MYGN	Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

Companion Diagnostic: Companion diagnostics are tests used to identify which patients are most likely to benefit from a particular therapy. They are used to identify the presence or absence of a biomarker that is associated with a particular disease or condition, and to determine the best course of treatment for a patient. Companion diagnostics are used to help physicians make more informed decisions about which treatments are most likely to be effective for a particular patient.